What You Need to Know About BioMarin's Vimizim Ahead of the FDA Decision

Developing treatments for rare disease is a risky proposition. Any number of bumps can derail clinical trials, and the lucky few that make it to market address small patient pools unlikely to produce blockbuster therapies.

http://ift.tt/1ewNmvP